? CANCER CONTROL AND SURVIVORSHIP The Cancer Control and Survivorship (CCS) Program of the Robert H. Lurie Comprehensive Cancer Center (LCC) is a multidisciplinary program focusing on three specific aims: (1) Measurement Science: improve the measurement, analysis and interpretation of patient-reported outcomes (PROs); (2) Survivorship Research: improve cancer survivorship by studying biological, behavioral and sociocultural determinants of optimal survivorship; and (3) Intervention Development and Delivery: develop and implement targeted interventions to promote cancer control and reduce acute and long-term effects of cancer and related therapies. The Program is comprised of 32 faculty members from 13 departments and 3 schools. Total peer-reviewed funding is $10,236,948 (direct), with $3,769,564 from the NCI and $6,467,384 from other peer-reviewed sources. During calendar year 2016, a total of 975 participants were enrolled in program studies, with 313 enrolled in intervention studies and 662 enrolled in observational or correlative studies. During the current funding period there were 575 cancer-relevant publications, with 21% representing intra-programmatic collaborations, 29% representing inter-programmatic collaborations, and 88% representing inter-institutional collaborations. Over the current funding period, the CCS Program has made significant gains and its members have conducted high impact studies. For example, CCS members have developed and implemented brief, validated and clinically-relevant PRO measures, and identified contextual and modifiable factors associated with health-related quality of life (HRQoL) during survivorship. CCS members have also contributed to our understanding of neural substrates of the toxic effects of chemotherapy using fMRI techniques, documented adherence to quality metrics to improve surgical oncology outcomes, and developed and implemented fertility preservation techniques for cancer patients and survivors. Studies have also developed optimal processes for survivorship care within our clinics and across our community. Our work is grounded in measurement and intervention science discoveries made and psychosocial interventions to reduce cancer burden in our communities. The LCC provides significant value to the CCS Program by providing pilot funds and access to shared resources. In turn, the CCS program adds value to the LCC with strong program leadership, CCS Program meetings and speaker series, catchment- relevant and translational research, and by promoting collaborative opportunities that impact the LCC catchment area. The LCC and CCS leadership have developed a strategic plan to guide our future vision. The primary goal is to further strengthen our research across our aims by adding depth and breadth. Over the next 5 years, we will expand into cancer care delivery, precision oncology, pediatric survivorship, and dissemination and implementation science. We intend to renew our successful T32 grant; and develop PO1 submissions in prostate cancer and lifestyle factors in cancer survivors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA060553-24S2
Application #
9771924
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Ptak, Krzysztof
Project Start
Project End
Budget Start
2018-08-01
Budget End
2019-07-31
Support Year
24
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Northwestern University at Chicago
Department
Type
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Nahum-Shani, Inbal; Smith, Shawna N; Spring, Bonnie J et al. (2018) Just-in-Time Adaptive Interventions (JITAIs) in Mobile Health: Key Components and Design Principles for Ongoing Health Behavior Support. Ann Behav Med 52:446-462
Kang, Hong-Jun; Song, Ha Yong; Ahmed, Mohamed A et al. (2018) NQO1 regulates mitotic progression and response to mitotic stress through modulating SIRT2 activity. Free Radic Biol Med 126:358-371
Long, Alan; Dominguez, Donye; Qin, Lei et al. (2018) Type 2 Innate Lymphoid Cells Impede IL-33-Mediated Tumor Suppression. J Immunol 201:3456-3464
Lewis, Phillip L; Su, Jimmy; Yan, Ming et al. (2018) Complex bile duct network formation within liver decellularized extracellular matrix hydrogels. Sci Rep 8:12220
Hong, Bong Jin; Iscen, Aysenur; Chipre, Anthony J et al. (2018) Highly Stable, Ultrasmall Polymer-Grafted Nanobins (usPGNs) with Stimuli-Responsive Capability. J Phys Chem Lett 9:1133-1139
Smith, Erica D; Garza-Gongora, Arturo G; MacQuarrie, Kyle L et al. (2018) Interstitial telomeric loops and implications of the interaction between TRF2 and lamin A/C. Differentiation 102:19-26
Hsiao, Hsi-Min; Fernandez, Ramiro; Tanaka, Satona et al. (2018) Spleen-derived classical monocytes mediate lung ischemia-reperfusion injury through IL-1?. J Clin Invest 128:2833-2847
Mehta, Amol; Awah, Chidiebere U; Sonabend, Adam M (2018) Topoisomerase II Poisons for Glioblastoma; Existing Challenges and Opportunities to Personalize Therapy. Front Neurol 9:459
Brown, Jessica H; Das, Prativa; DiVito, Michael D et al. (2018) Nanofibrous PLGA electrospun scaffolds modified with type I collagen influence hepatocyte function and support viability in vitro. Acta Biomater 73:217-227
Ntai, Ioanna; Fornelli, Luca; DeHart, Caroline J et al. (2018) Precise characterization of KRAS4b proteoforms in human colorectal cells and tumors reveals mutation/modification cross-talk. Proc Natl Acad Sci U S A 115:4140-4145

Showing the most recent 10 out of 1972 publications